Medication adherence to specific drug classes in chronic heart failure by Viana, M et al.
1018 Journal of Managed Care & Specialty Pharmacy JMCP October 2014 Vol. 20, No. 10 www.amcp.org
Medication Adherence to Specific  
Drug Classes in Chronic Heart Failure
Marta Viana, MSc; Olga Laszczynska, MSc; Sandra Mendes, MSc; Fernando Friões, MD;  
Patrícia Lourenço, MD; Paulo Bettencourt, MD, PhD; Nuno Lunet, MPH, PhD; and Ana Azevedo, MD, PhD
ABSTRACT
BACKGROUND: Adherence to medication is crucial to improve clinical 
outcomes in patients with heart failure (HF). However, at least 1 out of 
4 patients is nonadherent to his or her medication. Several studies have 
quantified medication adherence in HF patients, monitoring only 1 drug 
with the Medication Event Monitoring System (MEMS). Some authors have 
argued that monitoring 1 drug reflects the whole adherence behavior, 
although there is some evidence of important differences in adherence to 
distinct drug classes. Furthermore, medication characteristics could be a 
relevant predictor of adherence, and different drugs could pose different 
barriers to patients.
OBJECTIVES: To (a) quantify medication adherence to angiotensin-convert-
ing enzyme inhibitors (ACEI), beta blockers, and loop diuretics and (b) com-
pare the agreement in adherence among drug classes in chronic HF.
METHODS: Medication adherence to 3 different drugs was monitored using 
MEMS in 63 patients (81% male, mean age 63.5 years). Medication adher-
ence was measured as the percentage of prescribed doses effectively 
taken. Patients were considered to be adherent when at least 88% of 
prescribed doses were taken. Adherence agreement between drug classes 
was analyzed with Bland-Altman plots and Kappa coefficients. 
RESULTS: The mean adherence was 97.3% for ACEI, 97.2% for beta blockers, 
and 96.0% for loop diuretics. Individual patients did not adhere equally to all 
drug classes, with differences within the same patient ranging from -35% to 
33%. The proportion of patients classified as adherent was 77.8% to ACEI, 
69.8% to beta blockers, and 69.8% to loop diuretics. The agreement between 
each of 2 drugs regarding adherence was substantial (beta blocker vs. ACEI: 
K = 0.72; beta blocker vs. diuretic: K = 0.62; ACEI vs. diuretic: K = 0.72). If 
patients were classified as adherent and nonadherent based only on 1 drug, 
20% of patients would be misclassified regarding the other drugs.
CONCLUSIONS: Patients can adhere differently to medication used in HF 
treatment, with lowest adherence to loop diuretic and beta blockers and 
highest adherence to ACEI. Studies measuring medication adherence 
should always specify the drug class being analyzed and should not mix 
different drug classes to generalize about adherence behavior.
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RESEARCH
Heart failure (HF) is a syndrome caused by cardiac dysfunction, affecting 1%-2% of the adult population, with an incidence of 5-10 per 1,000 persons per year.1 
Its prevalence and incidence rise progressively with age in 
persons older than aged 50 years.1 Patients with HF require 
long-term pharmacological therapy in order to improve disease 
prognosis. The cornerstone of HF treatment includes the use 
of angiotensin-converting enzyme inhibitors (ACEI; or angio-
tensin receptor blockers (ARB) if ACEI is not tolerated), beta 
blockers, mineralocorticoid receptor antagonists (MRA), and 
diuretics.2,3 While diuretics are important to relieve symptoms, 
ACEIs, ARBs, MRAs, and beta blockers change the natural 
course of disease and are crucial to prevent hospitalizations 
and improve survival.2,3 
Despite the proven efficacy of recommended pharmacological 
therapy for patients with HF, adherence to treatments remains 
suboptimal, contributing to lower treatment effectiveness. It is 
estimated that at least 1 out of 4 patients with HF is nonadherent 
to his or her medication.4-6 Medication adherence is a complex 
phenomenon, influenced by a multitude of factors related to 
patients, diseases, therapies, health care systems, and socioeco-
nomic conditions.7 Among these, patient-related predictors have 
been extensively described in the literature, but age, gender, 
marital status, and education have failed to fully explain the 
variation in patient adherence.8 Some authors have argued that 
• Adherence to medication in heart failure (HF) remains subopti-
mal, contributing to lower treatment effectiveness. 
• Several studies have quantified medication adherence in HF 
patients, monitoring only 1 drug with the Medication Event 
Monitoring System (MEMS). 
What is already known about this subject
• Some authors have argued that monitoring 1 drug reflects the 
whole adherence behavior, although there is some evidence of 
important differences in adherence to distinct drug classes. 
• This study quantifies medication adherence to 3 different drug 
classes and analyzes the agreement in adherence among them. 
• One-fifth to one-third of the patients were nonadherent to medi-
cation, with lowest adherence to beta blockers and loop diuretics 
and highest to angiotensin-converting enzyme inhibitors (ACEI). 
• About 20% of the patients were adherent to 1 drug and nonadher-
ent to another, indicating that adherence can be variable accord-
ing to drug classes. 
• Studies measuring medication adherence should always specify 
the drug class being analyzed and should not mix different drug 
classes to generalize about adherence behavior.
What this study adds
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73.2 vs. 63.5 years, P < 0.001) and more likely to be women 
(35.3% vs. 19.1%, P = 0.077) and not married (47.1% vs. 20.6%, 
P < 0.007) with lower income (87.5% vs. 74.6, P = 0.148) and 
lower education (85.3% vs. 82.5%, P = 0.727).
Procedures
On the day of the scheduled medical appointment in the HF 
clinic, participants were invited to a meeting with a trained 
researcher in order to be provided with a set of monitors and 
instructions. The participants were asked to bring all of their 
ACEI, beta blocker, and loop diuretic medications. Those who 
agreed to participate signed a specific written informed con-
sent for this substudy, and each received 3 monitors: 1 for the 
ACEI, 1 for the beta blocker, and 1 for the loop diuretic. 
The MEMS caps have a microchip that records real-time 
data on the openings of the monitor. Each monitor had a label 
with the name of the corresponding medicine to allow patients 
there is no clear profile for nonadherent patients.9 Furthermore, 
several studies show that medication characteristics, such as 
adverse side effects,10 dosing frequency,5,11,12 and timing of 
administration,12 could be relevant predictors of adherence. 
Several studies have quantified medication adherence in 
patients with HF using electronic-monitoring devices, such as 
the Medication Event Monitoring System (MEMS).4,11,13-15 MEMS 
has been reported as a valid, reliable, and precise instrument,16 
providing detailed information about the medication-taking 
behavior that is not possible with other methods. Most previ-
ous studies of patients with HF have monitored only 1 drug 
with MEMS, arguing that monitoring 1 drug reflects the whole 
adherence behavior.4,11,13-15 However, this argument is not 
evidence based, and recent studies using different methods to 
measure adherence in patients with HF have reported differ-
ences in adherence depending on the drug class analyzed.10,17 
We, therefore, conducted this study of patients with HF to 
quantify medication adherence to ACEI, beta blockers, and 
loop diuretics using MEMS and to assess the degree of agree-
ment in adherence to different drug classes. In addition, we 
identified the patient and medication characteristics associated 
with adherence to all 3 of these drug classes.
■■  Methods
Study Design and Sample Selection
This observational study is based on a cohort of patients with 
chronic HF assembled with the main objective of analyzing the 
prognostic effect of drug therapy as used in routine. Between 
January 2011 and July 2012, we recruited patients followed at 
an outpatient clinic dedicated to HF patients—Hospital de São 
João, a tertiary-level teaching hospital located in the urban area 
of Porto, in the northern region of Portugal. The criteria to be 
enrolled in the study were a confirmed diagnosis of chronic HF 
according to the European Society of Cardiology criteria,2 with 
a history of systolic dysfunction and no hospitalizations for HF 
in the previous 3 months (n = 297). Patients were prospectively 
followed for 2 years, during which monthly contacts were 
established, either by telephone or face to face at scheduled 
clinical appointments. The study was approved by the Ethics 
Committee of Hospital de São João, and all participants pro-
vided written informed consent.
A subsample of patients from this cohort was consecutively 
selected to be monitored for 3 months with MEMS if they were 
aged 18 years or above; had a prescribed therapy from the 
HF outpatient clinic that included the simultaneous use of an 
ACEI, a beta blocker, and a loop diuretic; and who managed 
their own medications. 
A total of 97 patients were invited to be monitored, and 67 
accepted to participate. Among the latter, 2 patients did not use 
the monitors at all, and another 2 quit at some point during the 
first month, leaving 63 for analysis (Figure 1). Compared with 
participants, nonparticipants (n = 34) were older (mean age: 
Patients with HF enrolled in 
prospective cohort study, 
January 2011-July 2012  
(n = 297)
Substudy with MEMS monitoring 
started, September 2011  
(n = 275)
Eligible patients 
(n = 134)
Patients invited 
(n = 97)
Patients enrolled
(n = 67)
Patients with complete MEMS 
monitoring  
(n = 63)
 16  Dead
 4  Discharged from HF 
clinic
 2  Dropouts
91  No simultaneous  
ACEI + beta blocker  
+ loop diuretic
 12  Dead
 1  Discharged from HF 
clinic
 1 Dropouts from the 
prospective study
 3  Lost contacts
 20  No monitors available 
  1  Communication 
difficulties 
29  Refusals
 2 No use of the monitors
 2 Dropouts during the first 
month of monitoring
ACEI = angiotensin-converting enzyme inhibitor; HF = heart failure; 
MEMS = Medication Event Monitoring System.
FIGURE 1 Sample Selection Flowchart
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to distinguish them. In addition, each monitor was tagged with 
2 colored dots—one on the container and one on the cap—to 
avoid unintended swapping of caps. Patients were given verbal 
and written instructions on the use and refilling of monitors. 
Patients were instructed to open the monitors only to take 
their medications and afterwards to close them, making sure 
that each monitor was properly closed and that each cap was 
on the correct container. If patients had to take half a pill, they 
were instructed to open the monitor, remove a pill and break 
it in half, take a half, and put the other half back in the con-
tainer. We also asked patients to write down all extra openings, 
for refills or by mistake, in the log provided for this purpose. 
During the appointment, the researcher demonstrated how to 
use the monitors and asked the patients to repeat the procedure 
and explain back. The researcher filled the monitors for the first 
time; afterwards monitors were refilled by patients at home. 
During the monthly interviews of the prospective study, the 
researcher queried patients about the ongoing monitoring and 
asked if there were any questions that needed to be clarified. 
Participants were monitored for 3 months.
Data Collection and Definition of Variables
At the baseline of the prospective cohort study, clinical data 
were abstracted from the medical files using a standardized 
form comprising information on age, sex, disease etiology, 
and comorbidities. Left ventricular systolic dysfunction in the 
first appointment at the outpatient clinic was also collected, 
based on the measurement of left ventricular ejection fraction. 
Education, income, and marital status were updated by ques-
tionnaire upon entrance to the substudy. Income was assessed 
in comparison to the national minimum wage, which was at 
the time 485 euros per month. 
At the beginning of MEMS utilization, a trained researcher 
collected data from the patients’ medical records regarding 
current clinical data, including New York Heart Association 
(NYHA) functional class, duration of follow-up at the outpa-
tient clinic, and the total number of drugs prescribed. We con-
verted ramipril to the lisinopril equivalent using the dose ratio 
of 5:20, and similarly, we converted bisoprolol and nebivolol 
doses to the carvedilol equivalent using the dose ratio of 1:5. 
Data about patients’ hospitalizations during the monitoring 
period were also collected. 
Adherence data were downloaded to a computer and 
analyzed by AARDEX software (AARDEX Group, Ltd., Sion, 
Switzerland), which generated adherence indicators. We com-
puted the percentage of prescribed doses taken during the 
monitoring period (dose-count) and classified the patients as 
adherent to each of the medicines monitored when they took 
≥88% of the doses prescribed, based on previous research that 
demonstrated that this adherence rate is associated with better 
clinical outcomes in HF.4 All extra openings of the MEMS and 
periods in which patients were hospitalized were not consid-
ered in data analysis.
Data Analysis
Descriptive data are presented as percentages for categorical 
variables. Continuous variables are presented using mean with 
standard deviation or median with 25th-75th percentiles (P25-
P75), as appropriate. The chi-square test was used to compare 
proportions between groups. A P value of < 0.05 was consid-
ered to be statistically significant. 
To assess the level of agreement between adherence to 
ACEIs, beta blockers, and loop diuretics, we used Bland-Altman 
plots and Kappa coefficients. Bland Altman plots were used 
when considering adherence as a continuous variable, while 
Kappa coefficients and their 95% confidence intervals (CI) were 
used when adherence was defined as a dichotomous variable. 
Data analysis was carried out using STATA version 11 for 
Windows (StataCorp LP, College Station, TX). 
■■  Results
The characteristics of the 63 patients are presented in Table 1. 
The mean age was 63.5 years. Most patients were male (81.0%), 
married (79.4%), with less than 9 years of education (82.5%) 
and income lower than the national minimum wage (74.6%). 
The disease etiology was nonischemic for 57.1% of the patients, 
and among these, the main cause of HF was alcohol abuse 
(30.5%). Most patients had moderate-to-severe left ventricu-
lar systolic dysfunction (92.1%) at the time of diagnosis. The 
prevalence of important comorbidities ranged between 17.5% 
for chronic renal failure and 61.9% for dyslipidemia.
At the beginning of MEMS monitoring, patients had been 
followed in the outpatient clinic for 2.7 years, and most were 
in NYHA class I (54.0%) or II (38.1%). The median daily doses 
of ACEIs, beta blockers, and loop diuretics were 10 milligrams 
(mg) of lisinopril-equivalent, 25 mg of carvedilol-equivalent, 
and 40 mg of furosemide, respectively. Almost all patients had 
the ACEI prescribed once a day (98.4%), while a large propor-
tion of patients had the beta blocker (60.3%), as well as the 
loop diuretic (44.6%) prescribed twice daily. Regarding the 3 
drugs being monitored, most patients (61.9%) had at least 2 
different daily administrations, while only 8 (12.7%) took all 
the drugs at a single time. The mean number of all drugs taken 
per patient was 7.8.
Patients were monitored with MEMS for a median of 96 
(P25-P75: 89-105) days, with a minimum and a maximum of 
49 and 180 days, respectively. The median proportion of doses 
taken was 97.3% (P25-P75: 88.7-100.0) for ACEIs, 97.2% (P25-
P75: 79.6-99.1) for beta blockers, and 96.0% (P25-P75: 76.6-
98.9) for loop diuretics (Figure 2). On average, the difference 
in adherence to each of the drugs was small (beta blocker vs. 
ACEI: -3.4%; beta blocker vs. diuretic: -1.0%; ACEI vs. diuretic: 
-4.4%), but in individual patients, it ranged from -35% of 
doses to 33% of doses for specific drug classes, indicating that 
patients who failed drug doses were often not the same among 
the 3 drug classes (Figure 3).
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Among the 63 patients, 49 (77.8%) were classified as adher-
ent to ACEIs, 44 (69.8%) to beta blockers, and 44 (69.8%) to 
loop diuretics. Our results show that 81% of the patients were 
concordant, either adherent or nonadherent to the 3 drugs, 
while 19% of the patients were classified either as adherent or 
nonadherent, depending on the specific drug analyzed. Among 
the patients with a discordant classification, 4 (33.3%) patients 
were adherent to ACEIs and beta blockers and nonadherent to 
loop diuretics; 4 (33.3%) patients were adherent to ACEIs and 
loop diuretics and nonadherent to beta blockers; 2 (16.7%) 
patients were adherent to ACEIs and nonadherent to loop 
diuretics and beta blockers; and the other 2 (16.7%) patients 
were nonadherent to ACEIs and to 1 of the other drugs classes. 
Agreement in patient classification regarding adherence in each 
pair of drug classes was substantial (beta blocker vs. ACEI: 
K = 0.72; beta blocker vs. diuretic: K = 0.62; ACEI vs. diuretic: 
K = 0.72; Table 2).18
The characteristics of patients and therapeutic regimen 
according to the classification as adherent to all drugs, non-
adherent to all drugs, and nonadherent to 1 or 2 drugs are 
presented in Table 3. Unspecific nonadherence to all drugs was 
associated with younger age, while adherence to all drugs was 
associated with higher education and income, but the differ-
ences were not statistically significant. Higher doses of ACEIs 
and beta blockers and more complex regimens were associated 
with unspecific nonadherence, while dose and frequency of 
Sociodemographic characteristics
Age (years), mean [SD]  63.5 [13.2]
Male sex, n (%)  51 (81.0)
Education (years), n (%)
≤ 9  52 (82.5)
> 9  11 (17.5)
Income, n (%)a
≤ National minimum wage  44 (74.6)
> National minimum wage  15 (25.4)
Marital status, n (%)
Married  50 (79.4)
Single/divorced/widowed  13 (20.6)
Clinical characteristics
Moderate-severe LVSD, n (%)b  58 (92.1)
NYHA functional class, n (%)
Class I  34 (54.0)
Class II  24 (38.1)
Class III  5 (7.9)
HF etiology, n (%)
Ischemic  27 (42.9)
Nonischemic  36 (57.1)
Comorbidities, n (%)
Dyslipidemia  39 (61.9)
Hypertension  31 (49.2)
Diabetes mellitus  21 (33.3)
Chronic obstructive pulmonary disease  17 (27.0)
Chronic renal failure  11 (17.5)
Length of follow-up in the HF clinic (years),  
median (P25-P75) 
 2.7 (1.2-4.8)
Prescribed medication
Daily dose of ACEI (mg), median (P25-P75)c  10 (5-20)
Frequency of ACEI (times/day), n (%)
Once daily  62 (98.4)
Twice daily  1 (1.6)
Daily dose of beta blocker (mg), median (P25-P75)d  25 (25-50)
Frequency of beta blocker (times/day), n (%)
Once daily  25 (39.7)
Twice daily  38 (60.3)
Daily dose of diuretic (mg), median (P25-P75)  40 (40-100)
Frequency of diuretic (times/day), n (%)
Once daily  35 (55.6)
Twice daily  28 (44.4)
Schedules with HF medication: (ACEI, beta blocker, and diuretic), n (%)
Once daily  8 (12.7)
Twice daily  31 (49.2)
Three times daily  24 (38.1)
Total number of drugs, mean [SD]  7.8 [2.5]
an = 59.
bEjection fraction < 40%.
cLisinopril-equivalent.
dCarvedilol-equivalent. 
ACEI = angiotensin-converting enzyme inhibitor; HF = heart failure; LVSD = left 
ventricular systolic dysfunction; mg = milligram; NYHA = New York Heart 
Association; P25-P75 = 25th-75th percentiles; SD = standard deviation. 
TABLE 1 Sociodemographic and Clinical 
Characteristics of the Study Sample
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FIGURE 2 Adherence to Specific 
Drugs for Heart Failure
aDose-count is the percentage of prescribed doses taken.
ACEI = angiotensin-converting enzyme inhibitor.
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diuretics had a gradual inverse association with adherence 
(highest in unspecific nonadherents, intermediate in partial 
adherents, and lowest in adherents to all drugs). 
■■  Discussion
The present study provides evidence on medication adher-
ence simultaneously to 3 different drug classes—ACEIs, beta 
blockers, and loop diuretics—in HF patients. Overall, one-fifth 
to one-third of the patients took less than 88% of prescribed 
doses of each drug class and were thus classified as nonadher-
ent. The proportion of nonadherent patients was larger for 
beta blockers and loop diuretics than for ACEIs. Furthermore, 
although most patients were classified as adherent or nonad-
herent to all 3 drugs, about 20% of the patients were adherent 
to 1 drug and nonadherent to another, indicating that adher-
ence can be variable according to drug classes. 
In previous studies, medication adherence rates in patients 
with HF have been highly variable, ranging from 10% to 100%, 
which can be explained, at least partially, by the diversity 
of methods used to assess adherence.5,12,14,15,19-24 Medication 
adherence can be assessed using direct and indirect meth-
ods, but no gold standard is widely accepted. Direct methods 
include the measurement of serum or urine drug levels and 
biologic markers,25 providing information about the recent use 
of a drug; however, these depend on the variability in metabo-
lism and have shortcomings to quantify adherence in the long 
term.16 Medication adherence has been assessed indirectly in 
patients with HF using self-report,26 pill counts,27 prescription 
refill records,10,17 and electronic-monitoring devices.5,14,15,28,29 In 
our study, the adherence estimated using MEMS was consistent 
with other studies that measured medication adherence with 
the same method, among patients with HF.5,14,15,28,29 
Our data suggest that adherence between drug classes 
could be different in the same subject, indicating intrasubject 
disagreement in adherence. Previous studies have monitored 
only 1 drug with MEMS, assuming that adherence reflects an 
individual behavior.4,11,13-15 However, our results do not sup-
port this approach, and some recent studies using pharmacy 
refill data also suggested that it is not enough to monitor 1 
drug to understand patient behavior. Gislason et al. (2007) 
have reported different adherence estimates for inhibitors of 
the renin angiotensin system (RAS; 79%), beta blockers (65%), 
and spironolactone (56%).10 In a study with patients followed 
in an HF clinic, adherence was 93% for RAS inhibitors, 92% 
for beta blockers, and 86% for spironolactone after 1 year and 
90% for RAS inhibitors, 88% for beta blockers, and 74% for 
spironolactone after 3 years.17 These data support our results 
that patients can adhere differently to specific drug classes. 
and the assumption might be made that different drugs pose 
different barriers to adherence.
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Mean of dose-count diuretic and dose-count ACEI
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FIGURE 3 Agreement in Adherence to Different 
Drugs for Heart Failure
aDose-count is the percentage of prescribed doses taken.
ACEI = angiotensin-converting enzyme inhibitor; BB = beta blocker.
Di
ffe
re
nc
e 
(d
os
e-
co
un
t B
B—
do
se
-c
ou
nt
 A
CE
I)
Di
ffe
re
nc
e 
(d
os
e-
co
un
t d
iu
re
tic
—
do
se
-c
ou
nt
 A
CE
I)
Di
ffe
re
nc
e 
(d
os
e-
co
un
t d
iu
re
tic
—
do
se
-c
ou
nt
 B
B)
www.amcp.org Vol. 20, No. 10 October 2014 JMCP Journal of Managed Care & Specialty Pharmacy 1023
Medication Adherence to Specific Drug Classes in Chronic Heart Failure
several factors. First, loop diuretics and beta blockers were 
more frequently prescribed twice daily compared with ACEIs, 
and frequency of doses is a well-recognized predictor to non-
adherence.11,19,32-36 Second, patients that had beta blockers 
or loop diuretics prescribed twice daily had the second dose 
often prescribed in the middle of the day, which can represent 
a barrier to adherence, since it can interfere with the patients’ 
daily activities. Also, each of the drug classes is associated 
with different side effects, which can represent an important 
barrier to adherence.8 Patients on diuretics can experience an 
increase in urinary frequency, erectile dysfunction, and muscle 
cramps.37 Beta blockers can also cause erectile dysfunction, as 
well as dizziness, hyperglycaemia, claudication, and bradycar-
dia.38 These important side effects can make the management 
of these specific drug classes more difficult.
Adherence is influenced by a multitude of factors such 
as age, gender, marital status, socioeconomic status, educa-
tion, comorbidities, disease severity, and regimen complexity. 
Several studies have investigated the predictors of nonadher-
ence; however, the results are still inconsistent, demonstrating 
that there is no clear profile for nonadherent HF patients.9 
The complexity of the medication regimen and experienced 
side effects seem to be particularly important in explaining 
medication adherence. Our results indicate that patients with 
lower doses of ACEIs, beta blockers, and loop diuretics were 
more likely to be adherent to all drugs, corroborating previous 
research.11,19,32-36 Also, patients taking loop diuretics once daily 
were more likely to be adherent to all the drugs. The frequency 
of loop diuretics is inseparable from its dose, since patients tak-
ing higher doses have more frequent daily dosing. Therefore, 
The most common method to analyze adherence data has 
been to classify patients as adherent or nonadherent. However, 
the cutpoints that have been chosen are commonly arbitrary.4,30 
In order to provide a clinically relevant cutpoint in patients 
with HF, Wu et al. (2009) have demonstrated that medication 
adherence rates below 88% were associated with worse clinical 
outcomes, namely emergency room visits, hospitalizations, and 
mortality.4 Using this evidence-based cutpoint, our results have 
demonstrated a considerable proportion of patients that were 
nonadherent to ACEIs (22%), to beta blockers (30%), and to 
loop diuretics (30%). Two studies using the same cutpoint have 
reported proportions of nonadherent patients that differ from 
those observed in our sample. One study that measured adher-
ence to 1 drug—which could be either an ACEI, beta blocker, 
digoxin, or diuretic—reported that 44% were classified as 
nonadherent.4 Another study measuring adherence either to 
an ACEI or an ARB has described a proportion of nonadherent 
patients of 24%.5 The Heart Failure Adherence and Retention 
Trial (HART) found that 37% of the patients took less than 
80% of the prescribed medication.6 The differences observed in 
the proportions of nonadherent patients can be explained not 
only by the cutpoint being used, but also by the differences in 
the criteria to select the drug to be monitored. In these studies, 
patients were monitored for only 1 drug, which could be differ-
ent between studies and within the same study.4-6 
In our study, patients had better adherence to ACEIs than 
to beta blockers or loop diuretics. A meta-analysis that quanti-
fied the association between antihypertensive drug classes and 
adherence in clinical settings has also concluded that adher-
ence to ACEIs was superior to adherence to beta blockers and 
loop diuretics.31 This pattern by drug class can be related to 
Patient Classification, n (%)a Agreement
ACEI
Adherent Nonadherent Total K 95% CI
Beta blocker
Adherent  43 (68.3)  1 (1.6)  44 (69.9) 0.72 0.52-0.91
Nonadherent  6 (9.5)  13 (20.6)  19 (30.1)
Total  49 (77.8)  14 (22.2)  63 (100.0)
Diuretic
Adherent Nonadherent Total K 95% CI
Beta blocker
Adherent  39 (61.9)  5 (7.9)  44 (69.8) 0.62 0.41-0.84
Nonadherent  5 (7.9)  14 (22.2)  19 (30.1)
Total  44 (69.8)  19 (30.1)  63 (100.0)
Diuretic
Adherent Nonadherent Total K 95% CI
ACEI
Adherent  43 (68.3)  6 (9.5)  49 (77.8) 0.72 0.52-0.91
Nonadherent  1 (1.6)  13 (20.6)  14 (22.2)
Total  44 (69.9)  19 (30.1)  63 (100.0)
aPatients were classified as adherent when the prescribed number of doses taken exceeded 88%. 
ACEI = angiotensin-converting-enzyme inhibitor; CI = confidence interval; K = kappa coefficient.
TABLE 2 Agreement in Patient Classification Regarding Adherence to Different Drugs
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This study applies to a Portuguese setting, where the medi-
cation reimbursement scheme is embedded in the National 
Health Service, which is funded by general taxation and 
provides health coverage for the whole population. The costs 
of medication are partially supported by the government and 
partially by the patients. The reimbursement scheme is divided 
into 4 tiers, according to the essentiality of the drug.39 ACEIs, 
beta blockers, and loop diuretics are included in the second 
tier, which includes essential drugs for chronic diseases that 
are reimbursed for 69% of the drug price. Furthermore, an 
extra reimbursement of 15% can be applied to low-income 
patients. Thus, patients in our sample had costs with medica-
tion, and the level of reimbursement was uniform within the 
study sample. 
Due to the selection procedures and the participants’ char-
acteristics, as well as the characteristics of the Portuguese 
health care system, the generalizability of the results to the 
whole HF population should be done with caution. 
we cannot disentangle if adherence to loop diuretics is related 
to the frequency or to the dose. Furthermore, this relationship 
can be explained, to some extent, by reverse causality, since 
nonadherent patients may have had more severe symptoms 
and, consequently, higher doses of prescribed loop diuretics. 
Limitations
The design of this study offered the opportunity to measure 
simultaneously medication adherence to 3 different drugs 
classes using MEMS. However, there are some important limi-
tations of this study that need to be acknowledged. 
High adherence rates observed might be explained by 
patients’ selection criteria, since patients who were selected by 
doctors for the study and who agreed to participate might be 
more motivated to adhere to medication. Moreover, lower par-
ticipation was associated with older age and not being married. 
Although some studies found older age to have a positive effect 
on adherence, the results are still inconsistent.9 
Nonadherent to All Drugs
Nonadherent to 1 or 2 
Drugs Adherent to All Drugs
P Valuen (%) n (%) n (%)
Total  12 (19.1)  12 (19.1)  39 (61.9)
Patient characteristics
Aged ≤ 65 years  9 (75.0)  6 (50.0)  16 (41.0) 0.120
Male sex  9 (75.0)  9 (75.0)  33 (84.6) 0.641
Education ≤ 9 years  12 (100.0)  11 (91.7)  29 (74.4) 0.080
Income ≤ national minimum wage  11 (91.7)  10 (83.3)  23 (65.7) 0.151
Married  9 (75.0)  8 (66.7)  33 (84.6) 0.372
Moderate or severe LVSD  11 (91.7)  11 (91.7)  36 (92.3) 0.996
NYHA class I (vs. II-III)  6 (50.0)  6 (50.0)  22 (56.4) 0.884
Ischemic etiology  4 (33.3)  4 (33.3)  19 (48.7) 0.488
Hypertension  7 (58.3)  3 (25.0)  21 (53.9) 0.170
Diabetes mellitus  4 (33.3)  3 (25.0)  14 (35.9) 0.783
Dyslipidemia  9 (75.0)  6 (50.0)  24 (61.5) 0.450
Chronic obstructive pulmonary disease  3 (25.0)  3 (25.0)  11 (28.2) 0.962
Chronic renal failure  3 (25.0)  3 (25.0)  5 (12.8) 0.466
≤ 1 year of follow-up at the HF clinic  1 (8.33)  3 (25.0)  7 (18.0) 0.556
Medication characteristics
ACEI > 10 mg/daya  8 (66.7)  0 (0.0)  14 (35.9) 0.003
Beta blocker >25 mg/dayb  9 (75.0)  1 (8.3)  17 (43.6) 0.004
Diuretic > 40 mg/day  10 (83.3)  7 (58.3)  14 (35.9) 0.013
ACEI 2 times/day  1 (8.33)  0 (0.0)  0 (0.0) 0.115
Beta blocker 2 times/day  7 (58.3)  6 (50.0)  25 (64.1) 0.675
Diuretic 2 times/day  10 (83.3)  6 (50.0)  12 (30.7) 0.005
3 times/day for HF medicationc (vs. 1-2)  8 (66.7)  3 (25.0)  13 (33.3) 0.067
> 8 different drugs prescribed  10 (83.3)  9 (75.0)  29 (74.4) 0.811
aLisinopril-equivalent.
bCarvedilol-equivalent.
cAngiotensin-converting enzyme inhibitors, beta blocker, and diuretics.
ACEI = angiotensin-converting enzyme inhibitor; HF = heart failure; LVSD = left ventricular systolic dysfunction; mg/day = milligrams per day; NYHA = New York Heart 
Association.
TABLE 3 Patient and Medication Characteristics According to Agreement in 
Patient Classification Regarding Adherence to Different Drugs
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Fail. 2012;5(4):430-36. Available at: http://www.ncbi.nlm.nih.gov/
pubmed/22647773. Accessed July 30, 2014.
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http://www.ncbi.nlm.nih.gov/pubmed/17076693. Accessed July 30, 2014.
13. Wu JR, Lennie TA, De Jong MJ, et al. Medication adherence is a media-
tor of the relationship between ethnicity and event-free survival in patients 
with heart failure. J Card Fail. 2010;16(2):142-49. Available at: http://www.
ncbi.nlm.nih.gov/pubmed/20142026. Accessed July 30, 2014.
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adherence using a multidimensional adherence model in patients with heart 
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nih.gov/pubmed/18722327. Accessed July 30, 2014.
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vival in patients with heart failure. J Card Fail. 2008;14(3):203-10. Available 
at: http://www.ncbi.nlm.nih.gov/pubmed/18381183. Accessed July 30, 2014.
16. Farmer KC. Methods for measuring and monitoring medication regimen 
adherence in clinical trials and clinical practice. Clin Ther. 1999;21(6):1074-
90. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10440628. Accessed 
July 30, 2014.
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evidence-based pharmacotherapy in systolic heart failure and the transi-
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■■  Conclusions 
We demonstrated that a considerable proportion of patients 
were nonadherent to ACEIs, beta blockers, and loop diuretics. 
Furthermore, there are differences in adherence to different 
drug classes with lower adherence rates associated with loop 
diuretics and beta blockers and higher adherence rates associ-
ated with ACEIs. Also, patients could be adherent to 1 drug 
and nonadherent to another. Our findings indicate that studies 
measuring medication adherence should always specify the 
drug class being analyzed and should not mix different drug 
classes to generalize about adherence behavior. 
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